ARQT - Company ID 0001787306
The table below shows Arcutis Biotherapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$5.63M | -$112.16M | -$247.06M | -$257.71M | -$174.63M | -$113.03M |
| Capital expenditure | $686.00K | $143.00K | $428.00K | $333.00K | $995.00K | $321.00K |
| Investing cash flow | -$30.25M | $28.82M | $180.23M | -$87.20M | -$75.95M | -$181.82M |
| Dividends paid | - | - | - | - |
Arcutis Biotherapeutics, Inc. reported operating cash flow of -$5.63M for fiscal year 2025. That is up 95.0% from -$112.16M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow grew from -$14.09M (FY 2018) to -$5.63M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $6.97M | $66.20M | $101.32M | $301.80M | $281.95M | $298.14M |